NCT02616692View on ClinicalTrials.gov

HCC Patient Preferences in Japan

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

May 9, 2016

Primary Completion Date

October 7, 2016

Study Completion Date

October 7, 2016

Conditions
Hepatocellular Cancer
Interventions
DRUG

Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]

Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02616692 - HCC Patient Preferences in Japan | Biotech Hunter | Biotech Hunter